The role of miRNA in selected tumors development:
Potential use in diagnostics
-
Published:2021-01-18
Issue:
Volume:75
Page:1-11
-
ISSN:0032-5449
-
Container-title:Postępy Higieny i Medycyny Doświadczalnej
-
language:
-
Short-container-title:Postepy Hig Med Dosw
Author:
Paciorek Patrycja1, Żuberek Mariusz1, Grzelak Agnieszka1
Affiliation:
1. Katedra Biofizyki Molekularnej, Wydział Biologii i Ochrony Środowiska, Uniwersytet Łódzki
Abstract
MicroRNAs (miRNAs) are small ribonucleic acid molecules that, although not translated, perform
an important regulatory function in eukaryotic cells. Their physiological function is to
maintain cell homeostasis. Impaired miRNA expression can cause the development of many
diseases including cancer. MiRNA biological activity is based on inhibiting the formation of proteins,
including oncogenic and anti-oncogenic proteins. Mutations at the coding sites for such
miRNAs can lead to overproduction or reduction of the production of the above-mentioned
proteins. The discovery of miRNAs and understanding their role in the cell opened new ways
for diagnosing cancer. Therefore, changes in the level of relevant miRNAs in the bloodstream
or other bodily fluids can be a diagnostic marker of disease. Oncological diagnostics could be
based on examining the patient’s miRNA profile and comparing it with previously developed
profiles of miRNAs changes associated with the occurrence of a given type of cancer. Information
on changes in miRNA profiles that are key to regulating gene expression associated with
tumorigenic processes could contribute to the development of experimental therapies based
on restoring the original level of miRNA in cells and thereby restoring normal regulation of
gene expression. New methods of silencing and enabling miRNA expression may, in the future,
result in effective therapeutic solutions.
Publisher
Walter de Gruyter GmbH
Subject
Infectious Diseases,Microbiology (medical)
Reference120 articles.
1. Amr K.S., Ezzat W.M., Elhosary Y.A., Hegazy A.E., Fahim H.H.,Kamel R.R.: The potential role of miRNAs 21 and 199-a in early diagnosisof hepatocellular carcinoma. Gene, 2016; 575: 66–70 2. Anfossi S., Giordano A., Gao H., Cohen E.N., Tin S., Wu Q., GarzaR.J., Debeb B.G., Alvarez R.H., Valero V., Hortobagyi G.N., Calin G.A.,Ueno N.T., Woodward W.A., Reuben J.M.: High serum miR-19a levelsare associated with inflammatory breast cancer and are predictiveof favorable clinical outcome in patients with metastatic HER2+ inflammatorybreast cancer. PLoS One, 2014; 9: e83113 3. Antolin S., Calvo L., Blanco-Calvo M., Santiago M.P., Lorenzo-Patiño M.J., Haz-Conde M., Santamarina I., Figueroa A., Antón-AparicioL.M., Valladares-Ayerbes M.: Circulating miR-200c and miR-141and outcomes in patients with breast cancer. BMC Cancer, 2015;15: 297 4. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., HoonD.S.: Direct serum assay for microRNA-21 concentrations in earlyand advanced breast cancer. Clin. Chem., 2011; 57: 84–91 5. Basati G., Emami Razavi A., Abdi S., Mirzaei A.: Elevated level ofmicroRNA-21 in the serum of patients with colorectal cancer. Med.Oncol., 2014; 31: 205
|
|